Zobrazeno 1 - 10
of 113
pro vyhledávání: '"R Gregory Bociek"'
Autor:
Amit K Mittal, Nagendra K Chaturvedi, Rae A Rohlfsen, Payal Gupta, Avadhut D Joshi, Ganapati V Hegde, R Gregory Bociek, Shantaram S Joshi
Publikováno v:
PLoS ONE, Vol 8, Iss 8, p e70352 (2013)
Earlier, we reported that CTLA4 expression is inversely correlated with CD38 expression in chronic lymphocytic leukemia (CLL) cells. However, the specific role of CTLA4 in CLL pathogenesis remains unknown. Therefore, to elucidate the possible role of
Externí odkaz:
https://doaj.org/article/3ebf534eacfa42628eafca56b4f52f16
Autor:
Julie M. Vose, Siddhartha Ganguly, Philip J. Bierman, R. Gregory Bociek, Matthew Lunning, Liz Lyden, Jane L. Meza, Paolo F. Caimi, James O. Armitage
Publikováno v:
British Journal of Haematology.
Autor:
R. Gregory Bociek, Michelle A. Fanale, Philip J. Bierman, Matthew A. Lunning, Avyakta Kallam, Mary Jo Lechowicz, Julie M. Vose, Swaminathan P. Iyer, Mridula Krishnan, James O. Armitage
Publikováno v:
Annals of Hematology. 101:335-340
Peripheral T-cell lymphomas (PTCL) are a unique subset of lymphomas with a poor prognosis due to limited treatment options. We performed a phase 1 study of carfilzomib in patients with relapsed/refractory PTCL to determine the safety profile and the
Autor:
Connie Lee Batlevi, Yvette Kasamon, R. Gregory Bociek, Peter Lee, Lia Gore, Amanda Copeland, Rachel Sorensen, Peter Ordentlich, Scott Cruickshank, Lori Kunkel, Daniela Buglio, Francisco Hernandez-Ilizaliturri, Anas Younes
Publikováno v:
Haematologica, Vol 101, Iss 8 (2016)
Classical Hodgkin lymphoma treatment is evolving rapidly with high response rates from antibody-drug conjugates targeting CD30 and immune checkpoint antibodies. However, most patients do not achieve a complete response, therefore development of novel
Externí odkaz:
https://doaj.org/article/350518e891484644bc73ce19e24ea1ae
Preferences of adults with cancer for systemic cancer treatment: do preferences differ based on age?
Autor:
Julie M. Vose, Christopher S. Wichman, Bunny Pozehl, Meaghann S. Weaver, Alfred L. Fisher, Prajwal Dhakal, R. Gregory Bociek, Vijaya Raj Bhatt
Publikováno v:
Future Oncol
Background: We used the Therapy Preference Scale, a 30-item questionnaire, to determine cancer treatment preferences of adults with cancer. Methods: We used Wilcoxon’s rank sum test and Fisher’s exact test to compare the preferences of younger (
Autor:
Mridula, Krishnan, R Gregory, Bociek, Michelle, Fanale, Swaminathan P, Iyer, Mary Jo, Lechowicz, Philip J, Bierman, James O, Armitage, Matthew, Lunning, Avyakta, Kallam, Julie M, Vose
Publikováno v:
Annals of hematologyReferences. 101(2)
Peripheral T-cell lymphomas (PTCL) are a unique subset of lymphomas with a poor prognosis due to limited treatment options. We performed a phase 1 study of carfilzomib in patients with relapsed/refractory PTCL to determine the safety profile and the
Autor:
Heather Nutsch, Basem M. William, Julie M. Vose, Javeed Iqbal, Anas Younes, R. Gregory Bociek, Jayadev Manikkam Umakanthan, Philip J. Bierman, Alyssa Bouska, Mathew Lunning, Valerie Shostrom, Connie Lee Batlevi, Lynette M. Smith, James O. Armitage
Publikováno v:
Br J Haematol
Non-Hodgkin lymphoma (NHL) is one of the most prevalent cancers in the Western world with an increasing incidence in US (Zelenetz, et al 2010) This group of lymphomas encompasses a heterogeneous group of diseases with a wide range of histology, patho
Autor:
Jennifer N. Sanmann, Kathleen Kaiser-Rogers, Jayadev Manikkam Umakanthan, R. Gregory Bociek, Steven M Johnson, Yuri Fedoriw, Nathan D. Montgomery, Ji Yuan
Publikováno v:
Human Pathology. 80:192-200
High-grade B-cell lymphomas with MYC, BCL2, and/or BCL6 rearrangements, "double-hit" or "triple-hit" lymphomas (DTHL), are aggressive neoplasms associated with a poor prognosis. A t(3;8)(q27;q24) rarely occurs in B-cell lymphomas that results in a un
Autor:
Yinghui Wang, Ann S. LaCasce, Andres Forero-Torres, Eric C. Cheung, Jeffrey Matous, Howland E. Crosswell, R. Gregory Bociek, Edward Agura, Ahmed Sawas, Neil C Josephson, Ranjana H. Advani, Caroline Behler, Miguel Islas-Ohlmayer, Stephen M. Ansell, Julie M. Vose, Owen A. O'Connor, Paolo Caimi
Publikováno v:
British Journal of Haematology. 189
Autor:
Zaid S. Al-Kadhimi, Avyakta Kallam, R. Gregory Bociek, Apar Kishor Ganti, Valerie Shostrom, Krishna Gundabolu, Muhamed Baljevic, Christopher D'Angelo, Lynette M. Smith, Vijaya Raj Bhatt, Matthew A. Lunning, Lori J. Maness, Julie M. Vose
Publikováno v:
Blood. 138:1069-1069
Background: Acute Lymphoblastic Leukemia (ALL) outcomes have significantly improved over time with multi-agent chemotherapy, and the addition of asparaginase (ASP) has demonstrated the ability to prolong overall survival. ASP has multiple toxicities,